Hybrid dual recombinant AAV vector systems for gene therapy

Abstract

The invention relates to constructs, vectors, relative host cells and pharmaceutical compositions which allow an effective gene therapy, in particular of genes larger than 5 Kb by using an improved hybrid dual recombinant AAV vector system.

Claims

1. A hybrid dual rAAV (hdrAAV) vector system suitable for expressing the coding sequence of ABCA4 in a host cell, comprising: a) a first rAAV vector containing a first polynucleotide comprising in a 5′-3′ direction: a 5′-inverted terminal repeat (5′-ITR) sequence; a human rhodopsin kinase (RK) promoter sequence; the 5′ end portion of said coding sequence of ABCA4, said 5′ end portion being operably linked to and under control of said promoter; the 5′ end portion of a sequence of a synthetic intron comprising a nucleic acid sequence of a splicing donor (SD) signal (SEQ ID NO: 1); a nucleic acid sequence of a recombinogenic region derived or originating from alkaline phosphatase (AP); and a 3′-inverted terminal repeat (3′-ITR) sequence; and b) a second rAAV vector containing a second polynucleotide comprising in a 5′-3′ direction: a 5′-inverted terminal repeat (5′-ITR) sequence; a nucleic acid sequence of a recombinogenic region derived or originating from alkaline phosphatase (AP); the 3′ end portion of a sequence of a synthetic intron comprising a branch site and a polypyrimidine tract (SEQ ID NO: 2); a nucleic acid sequence of a splicing acceptor (SA) signal; the 3′ end of said ABCA4 coding sequence; a poly-adenylation signal nucleic acid sequence; and a 3′-inverted terminal repeat (3′-ITR) sequence.

2. The hdrAAV vector system of claim 1, wherein the recombinant AAV vectors are selected from the serotype 2, serotype 4, serotype 5 or serotype 8.

3. The hdrAAV vector system of claim 1, wherein the first rAAV vector comprises SEQ ID NO: 13 (AAV-RK-5′ABCA4-mAP vector) and the second rAAV vector comprises SEQ ID NO: 14 (AAV-mAP-SA-3′ABCA4-pA vector).

4. An isolated host cell which has been transduced, transformed or transfected with the hybrid dual viral vector of claim 1.

5. A pharmaceutical composition comprising the hybrid dual viral vector system of claim 1.

6. A pharmaceutical composition comprising the isolated host cell of claim 4 and a pharmaceutically acceptable vehicle.

7. A method of treating a pathology or disease characterized by a retinal degeneration in a subject in need thereof, comprising a step of administering a therapeutically effective amount of the hybrid dual viral vector system according to claim 1 or an isolated host cell comprising said hybrid dual viral vector system.

8. The hdrAAV vector system of claim 1, wherein the recombinogenic region AP comprises SEQ ID NO: 3, SEQ ID No. 4, SEQ ID No. 5, or SEQ ID No. 6.

9. The hdrAAV vector system of claim 1, wherein the 5′ end portion of the coding sequence comprises SEQ ID NO: 7 (exons 1-21) and the 3′ end of said coding sequence comprises SEQ ID NO: 8 (exons 22-50).

10. The hdrAAV vector system of claim 1, wherein the first polynucleotide comprises SEQ ID NO: 10 (RK-5′ABCA4-SD-AP), and the second polynucleotide comprises SEQ ID NO: 11 (AP-SA-3′ABCA4-pA).

11. The pharmaceutical composition of claim 5, wherein the recombinant AAV vectors are selected from serotype 2, serotype 4, serotype 5 or serotype 8.

12. The pharmaceutical composition of claim 5, wherein the first rAAV vector comprises SEQ ID NO: 13 (AAV-RK-5′ABCA4-mAP vector) and the second rAAV vector comprises SEQ ID NO: 14 (AAV-mAP-SA-3′ABCA4-pA vector).

13. The pharmaceutical composition of claim 5, wherein the recombinogenic region AP comprises SEQ ID NO: 3, SEQ ID No. 4, SEQ ID No. 5, or SEQ ID No. 6.

14. The pharmaceutical composition of claim 5, wherein the 5′ end portion of the coding sequence comprises SEQ ID NO: 7 (exons 1-21) and the 3′ end of said coding sequence comprises SEQ ID NO: 8 (exons 22-50).

15. The pharmaceutical composition of claim 5, wherein the first polynucleotide comprises SEQ ID NO: 10 (RK-5′ABCA4-SD-AP) and the second polynucleotide comprises SEQ ID NO: 11 (AP-SA-3′ABCA4-pA).

16. The method of claim 7, wherein the recombinant AAV vectors of the hdrAAV vector system are selected from serotype 2, serotype 4, serotype 5 or serotype 8.

17. The method of claim 7, wherein the first rAAV vector comprises SEQ ID NO: 13 (AAV-RK-5′ ABCA4-mAP vector), and the second rAAV vector comprises SEQ ID NO: 14 (AAV-mAP-SA-3′ABCA4-pA vector).

18. The method of claim 7, wherein the recombinogenic region AP comprises SEQ ID NO: 3, SEQ ID No. 4, SEQ ID No. 5, or SEQ ID No. 6.

19. The method of claim 7, wherein the 5′ end portion of the coding sequence comprises SEQ ID NO: 7 (exons 1-21) and the 3′ end of said coding sequence comprises SEQ ID NO: 8 (exons 22-50).

20. The method of claim 7, wherein the first polynucleotide comprises SEQ ID NO: 10 (RK-5′ABCA4-SD-AP) and the second polynucleotide comprises SEQ ID NO: 11 (AP-SA-3′ ABCA4-pA).

Description

FIGURES

(1) FIG. 1. Schematic representation of the 5′ and 3′ hybrid dual AAV vector genomes for ABCA4 gene transfer.

(2) FIG. 2. Schematic representation of the control plasmids for ABCA4 expression in vitro.

(3) FIG. 3. Detection of AAV-5′ABCA4 and AAV-3′ABCA4 vector recombination in vitro by PCR. (A) Schematic representation of the expected DNA sequence and PCR amplicons for AP-mediated recombination products and for control plasmid pCMV-5′ABCA4-mAP-3′ABCA4-pA (upper picture), and for control plasmid pCMV-5′ABCA4-3′ABCA4-pA (lower picture). Arrows represent RTfor and RTrev PCR primers, and size of the expected PCR products are indicated. (B) Detection of ABCA4 5′/3′ junctions by PCR in COST cells following plasmid transfection or AAV2/5 infection.

(4) FIG. 4. Detection of ABCA4 mRNA in vitro by RT-PCR. (A) Schematic representation of the expected sequence for DNA and unspliced RNA (upper picture) and for the spliced polyA+ mRNA (lower picture). PCR primers are indicated by arrows and expected PCR products are shown with their size indicated. (B) Detection of ABCA4 mRNA expression by RT-PCR in HEK293 cells following plasmid transfection or AAV2/5 infection.

(5) FIG. 5. Detection of ABCA4 protein expression by immuno-fluorescence staining on HeLa cells following plasmid transfection or AAV2/5 infection (+/−Ad5).

(6) FIG. 6. Detection of the dual ABCA4 vectors DNA by PCR following intra-muscular injection in C57/BL6 mice. (A) Schematic representation of the expected DNA sequence and PCR amplicons for dual AAV AP-mediated recombination products and for control plasmid pCMV-5′ABCA4-mAP-3′ABCA4-pA Arrows represent PCR primers, and size of the expected PCR products are indicated. (B) PCR results obtained with mouse muscles injected injected or not with the dual AAV5-ABCA4 vectors. Samples were: control mouse injected with PBS (C), mice injected with the dual AAV5-ABCA4 vectors (A1 and A2), non-injected or injected muscles (− or +), pCMV-5′ABCA4-mAP-3′ABCA4 plasmid DNA (P), and no template control (N).

(7) FIG. 7. Detection of ABCA4 mRNA by RT-PCR following intra-muscular injection of the dual AAV5-ABCA4 vectors in C57/BL6 mice. (A) Schematic representation of the expected sequence for DNA and unspliced RNA (upper picture) and for the spliced polyA+ mRNA (lower picture). PCR primers are indicated by arrows and expected PCR products are shown with their size indicated. (B) RT-PCR results obtained with mouse muscles injected or not with the dual AAV5-ABCA4 vectors. Samples were: mouse A1 non-injected (1) and dual AAV injected muscles (2 and 3), mouse A2 non-injected (4) and dual AAV injected muscles (5 and 6), mouse C non-injected muscle (7), pCMV-5′ABCA4-mAP-3′ABCA4 plasmid DNA (8), and no template control (9). Muscle RNA samples were reverse transcribed (+) or not (−) with M-MLV RT prior to PCR.

(8) FIG. 8. Detection of ABCA4 protein expression by immuno-fluorescence staining of muscle cryosection following intra-muscular injection of the dual AAV5 ABCA4 vectors in C57/BL6 mice. Cell nuclei appear in grey and the ABCA4 protein in white (ABCA4-positive muscle fibers indicated by white arrows).

(9) FIG. 9. Human ABCA4 transcript is detected by RT-qPCR analysis of injected Abca4.sup.−/− mouse eyes in two independent experiments. A) Five weeks post-injection of the dual AAV2/5 ABCA4 vectors, an ABCA4 transcript was detected in the neuroretina of injected Abca4.sup.−/− mice (72 Inj; 99 Inj). No transcript was detected in the neuroretinas from control Abca4.sup.+/− (69+/−) and non-injected Abca4.sup.−/− (71 NI) mice. B) Four weeks post-injection of the dual AAV2/5 ABCA4 vectors, an ABCA4 transcript was detected in the neuroretina of injected Abca4.sup.−/− mice (Inj 242; Inj 211). No transcript was detected in the neuroretinas from control Abca4.sup.+/+ (WT 227) and non-injected Abca4.sup.−/− (KO 231) mice. As a positive control for the qPCR reaction, an ABCA4 transcript was detected in COS cells transfected with the plasmid pCMV-5′ABCA4-3′ABCA4-pA (COS ABCA4) as compared to non-transfected (NT) cells.

(10) FIG. 10. Human ABCA4 transcript is detected by RT-qPCR analysis of injected Abca4.sup.−/− mouse eyes using different vector combinations. Seven weeks post-injection of the dual AAV2/5 ABCA4 vectors, a human ABCA4 transcript was detected in the neuroretina of injected Abca4.sup.−/− mice (Inj 728, -781, -786, -814). Mice 728 and 781 were injected with the CMV-5′ABCA4-mAP vector and the mAP-3′ABCA4 vector. Mice 786 and 814 were injected with the RK-5′ABCA4-mAP vector and the mAP-3′ABCA4 vector. No transcript was detected in the neuroretinas from control Abca4.sup.+/+ (WT 742) and non-injected Abca4.sup.−/− (KO 737) mice.

(11) FIG. 11. Human ABCA4 transcript is detected by RT-qPCR analysis of injected rat eyes using different vector combinations. Eight weeks after vector injections, a human ABCA4 transcript was detected in the neuroretina of rats injected with the dual AAV2/5 ABCA4 vectors. Rats C1 and C2 were injected with the RK-5′ABCA4-mAP vector and the mAP-3′ABCA4 vector. Rats D1 and D2 were injected with the CMV-5′ABCA4-mAP vector and the mAP-3′ABCA4 vector. No transcript was detected in the neuroretina of rats injected with the RK-5′ABCA4-mAP (A1 and A2) or the mAP-3′ABCA4 (B1 and B2) vector alone, and in the non-injected rat (NI).

EXAMPLE

(12) Material & Methods

(13) Plasmid Constructions:

(14) The split ABCA4 coding sequence (from Genbank NM_000350.2), the intronic sequences, the AP-derived recombinogenic sequence and the short poly-adenylation sequence were designed in silico based on published sequences. DNA containing the designed sequences was obtained by gene synthesis.
For AAV vector construction, sequences were assembled into a kanamycin-resistant AAV-2 plasmid backbone (pSSV9Kana) by standard cloning using suitable restriction endonucleases. The ITR-flanked genome content of the vectors is described below and in FIG. 1.
For construction of the AAV-5′ABCA4 vector, the human cytomegalovirus (CMV) immediate-early enhancer/promoter from pcDNA3.1 (Invitrogen), or the human rhodopsin kinase (RK) core promoter (Khani et al., IOVS 2007), was cloned upstream of a fragment including a consensus Kozak sequence, exons 1 to 21 of the human ABCA4 coding sequence, the splice donor sequence (SD) from the chimeric intron of pCI-Neo (Promega), and a human alkaline phosphatase (AP)-derived sequence corresponding to that described by Ghosh et al. (Mol Ther 2008), except that all ATG codons on both DNA strands (but one) were removed. The overall vector genome length (from ITR to ITR) was 5166 bp with the CMV promoter or 4745 bp with the RK promoter.
For construction of the AAV-3′ABCA4 vector, the same AP-derived sequence as in the 5′ vector was cloned upstream of the branch site, polypyrimidine tract and splice acceptor sequence from pCI-Neo chimeric intron (Promega), exons 22 to 50 of the human ABCA4 coding sequence, and a synthetic polyadenylation signal from pCI-Neo (Promega). The overall vector genome length (from ITR to ITR) was 5024 bp.
For functional testing of our designed ABCA4 expression system in vitro, two control plasmids were constructed into a pBlueScript plasmid backbone (FIG. 2):
Plasmid pCMV-5′ABCA4-mAP-3′ABAC4 contains the expression cassette that should be reconstituted upon homologous recombination between the 5′ and 3′ vectors, i.e. with the 5′ and 3′ parts of the ABCA4 coding sequence separated by the chimeric intron containing the AP-derived recombinogenic sequence. Plasmid pCMV-5′ABCA4-3′ABCA4 contains the same expression cassette except that the AP sequence was deleted from the intron.
AAV Vector Production:
AAV2/5 vector production was achieved by double transfection of HEK293 cells (Grimm et al., 2003). The helper plasmid used was pDP5-Kana, a derivative of pDP5rs (Grimm et al., 2003) into which ampicillin resistance was replaced with kanamycin resistance and the DsRed expression cassette was deleted. Cells grown in CellStack-5 culture chambers were co-transfected with helper plasmid pDP5-Kana together with each AAV vector plasmid (pSSV9Kana-CMV-5′ABAC4-mAP, pSSV9Kana-RK-5′ABAC4-mAP or pSSV9Kana-mAP-3′ABCA4-pA), and the AAV particles were harvested from both cells and culture supernatant at 96 h post-transfection. AAV from the supernatant was precipitated with PEG-8000, and vector particles were purified through two round of CsCl gradient ultracentrifugation as previously described (Ayuso et al., Gene Ther 2010).
Full AAV particles, i.e. encapsidated vector genomes (vg), were quantified by dot blot hybridization, and infectious AAV particles were quantified by the infectious center assay (ICA) on HeRC32 cells as previously described (Salvetti et al, Hum Gene Ther 1998). The probe used for both dot blot and ICA was generated with the PCR Fluorescein Labelling Mix (Roche), using primers hPLAP326sens and hPLAP785anti and pCMV-5′ABCA4-mAP-3′ABCA4 plasmid as the template DNA. Following hybridization, detection was performed using the CDP-Star ready-to-use labelling kit (Roche).

(15) ABCA4 Gene Transfer In Vitro:

(16) HEK293, HeLa and COS-7 cells were maintained in Dulbecco's modified Eagle medium (DMEM) containing 2 mM L-Glutamine and 4.5 g/L glucose (Sigma-Aldrich), supplemented with 10% fetal bovine serum (HyClone). AAV infections were performed in DMEM supplemented with 2% fetal bovine serum containing the AAV2/5 vectors, with or without adenovirus type 5. Plasmid transfection was performed by the calcium phosphate precipitation method.

(17) For PCR and RT-PCR analysis, cells were harvested 48 (with adenovirus) or 72 (without adenovirus) hours after infection or transfection and washed in 1×PBS. For PCR, total DNA was extracted using the NucleoSpin Blood kit (Macherey-Nagel). For RT-PCR, total RNA was extracted using Trizol reagent (Life Technologies). Poly-adenylated mRNA were reverse-transcribed into cDNA with M-MLV Reverse Transcriptase (Life Technologies) using oligo(dT) primers. PCR amplifications were performed on total DNA or cDNA with GoTaq DNA polymerase, using primers ABCA4-RTfor and ABCA4-RTrev (FIGS. 3.A and 4.A). For immuno-fluorescence staining, cells were fixed 72 hours after infection or transfection in PBS containing 2% paraformaldehyde, and permeabilized in PBS, 0.2% Triton X-100. Cells were then incubated with anti-ABCA4 mouse monoclonal antibody 3F4 (Santa Cruz), and then with anti-mouse AlexaFluor-488 antibody (Life technologies). Slides were finally mounted with Prolong Gold antifade reagent (Life Technologies) and observed with a Nikon Eclipse 90i microscope.

(18) ABCA4 Gene Transfer in Mouse Muscles In Vivo:

(19) For ABCA4 gene transfer in the skeletal muscle, a mix of AAV2/5-CMV-5′ABCA4-mAP and AAV2/5-mAP-3′ABCA4 vectors at 8.4×10.sup.11 vg/mL each was injected into the tibialis anterior muscles of two 8-weeks hold C57/BL6 mice (A1 and A2). Two legs were injected with ˜30 μL of vector mix, i.e. ˜2.5×10.sup.10 vg of each vector per injected muscle (˜5.0×10.sup.10 total vg/muscle). One control mouse (C) was injected the same way with buffer (DPBS) alone. All three mice were euthanized 1 month post-injection for analysis of injected and non-injected muscles.

(20) For PCR analysis, total DNA was extracted from muscles samples using a TissueLyser II device (Qiagen) and Gentra Puregene reagents (Qiagen). PCR was performed with GoTaq DNA polymerase (Promega) using primers ABCA4-F1 and -R1, ABCA4-4088s and -4497as and ABCA4-RTfor and -RTrev, to detect ABCA4 5′ and 3′ends as well as junctions between the 5′ABCA4 and the 3′ABCA4 vectors (FIG. 6.A).
For RT-PCR analysis, total RNA was extracted from muscles using a TissueLyser II device (Qiagen) and Trizol reagent (Life Technologies), and poly-adenylated mRNA were reverse-transcribed or not into cDNA with M-MLV Reverse Transcriptase (Life Technologies) using oligo(dT) primers. PCR was performed with KOD Xtrem DNA polymerase (Novagen) using primers ABCA4-5P and -RTrev, or ABCA4-RTfor and -3P, in order to amplify the full-length ABCA4 mRNA as two overlapping fragments (FIG. 7.A).
For immuno-fluorescence microscopy analysis, muscle cryosections were fixed with 4% paraformaldehyde for 10 min at room temperature, permeabilized with 0.2% Triton X-100, and incubated in blocking buffer (20% goat serum) during 30 min. They were then incubated overnight with anti-ABCA4 mouse monoclonal antibody 3F4 (Santa Cruz), and then with anti-mouse AlexaFluor-488 antibody (Life technologies). Sections were then incubated with DRAQ5 (Biostatus Limited) to counterstain nuclei, and pictures were acquired by confocal microscopy. Stained muscle sections were mounted using Prolong Gold antifade reagent (Life Technologies) and observed with a Nikon Eclipse TE-2000 confocal microscope.

(21) ABCA4 Gene Transfer in the Mouse Retina:

(22) Abca4.sup.−/− mice, generated by replacing exon 1 of the Abca4 gene by a LacZ/neo cassette, were purchased from Lexicon Pharmaceuticals. All animal breeding and experiments were carried out in accordance with the European and National guidelines for the care and use of laboratory animals (Council Directive 86/6009/EEC). For subretinal injections, eight-week-old mice were anesthetized with 70 mg/kg ketamine and 28 mg/kg xylazine and the pupils were dilated with a drop of 0.5% tropicamide (Mydiatricum, Théa). The cornea was covered with a drop of Lacryvisc (Alcon) and a glass-coverslip. Under a surgical microscope, a mix of 1.4 to 2.8×10.sup.9 vg of AAV2/5-CMV-5′ABCA4-mAP and 1.2 to 2.4×10.sup.9 vg of AAV2/5-mAP-3′ABCA4 vectors, or a mix of 1.5 to 5×10.sup.9 vg of AAV2/5-RK-5′ABCA4-mAP and 5×10.sup.9 of AAV2/5-mAP-3′ABCA4 vectors in a total volume of 2 μL was administered by subretinal injection into the eyes of Abca4.sup.−/− mice.

(23) For RT-qPCR analysis, the neuroretinas were dissected and snap-frozen prior to RNA isolation with RNeasy Mini kit, (Qiagen) and cDNA synthesis was carried out with SuperScript III Reverse Transcriptase (Invitrogen) according to the manufacturer's recommendations. Quantitative PCR analysis was performed using AmpliTaq Gold® 360 Master Mix (Applied Biosystems) and qPCR analysis using LightCycler® 480 SYBR Green I Master (Roche).

(24) ABCA4 Gene Transfer in the Rat Retina In Vivo:

(25) Sprague Dawley CD rats were purchased from Charles River and were handled in accordance with the Guide for the Care and Use of Laboratory Animals. For subretinal injections, three months-old rats were anesthetized with 50 mg/kg ketamine and 6 mg/kg xylazine, and an additional local anesthesia was achieved with a drop of oxybuprocaine chlorydrate (1.6 mg/0.4 mL). The pupils were dilated with a drop of 0.5% tropicamide (Mydiatricum, Théa), and subretinal injections were performed under a surgical microscope and controlled by eye fundus examination. Injected eyes were finally covered with Sterdex anti-inflammatory ointment. Animals were injected with either 3.7×10.sup.9 vg of AAV2/5-RK-5′ABCA4-mAP vector alone, 3.7×10.sup.9 vg of AAV2/5-mAP-3′ABCA4 vector alone, a mix of 1.85×10.sup.9 vg of AAV2/5-RK-5′ABCA4-mAP and 1.85×10.sup.9 vg of AAV2/5-mAP-3′ABCA4 vectors, or a mix of 1.85×10.sup.9 vg of AAV2/5-CMV-5′ABCA4-mAP and 1.85×10.sup.9 vg of AAV2/5-mAP-3′ABCA4 vectors, in a total volume of 5 μL.

(26) For RT-qPCR analysis, the neuroretinas were dissected and snap-frozen prior to RNA isolation with NucleoSpin RNA kit (Macherey-Nagel), and cDNA synthesis was carried out with M-MLV Reverse Transcriptase (Invitrogen) according to the manufacturer's recommendations. Quantitative PCR analysis was performed using SYBR qPCR Premix Ex Taq (Takara Bio).
Results

(27) Efficient Production of the Dual AAV2/5-ABCA4 Vectors:

(28) Production of our dual vectors, AAV2/5-CMV-5′ABCA4-mAP and AAV2/5-mAP-3′ABCA4, was effective despite the large size of the vector genomes which are close to the maximum packaging capacity of AAV, that is about 5.1-5.2 kb (Wu et al., Mol Ther 2010). The data (table 1) demonstrated correct production levels (around 10.sup.13 vg per CellStack-5 culture chamber), and a full (vg) to infectious particles ratio—indicative of vector quality—equivalent to that of a standard, regular size, AAV2/5 vector.

(29) TABLE-US-00001 TABLE 1 Representative AAV2/5 particles yield obtained with the dual ABCA4 vectors. Total full vector particles (vg) and infectious vector particles (ip) were purified from one transfected CellStack-5 culture chamber and titrated by dot blot hybridization and ICA. AAV2/5 vector total vg total ip vg/ip ratio CMV-5′ABCA4-mAP 9.1 × 10.sup.12 1.6 × 10.sup.9 5.8 × 10.sup.3 mAP-3′ABCA4-pA 1.0 × 10.sup.13 1.5 × 10.sup.9 6.8 × 10.sup.3

(30) ABCA4 Gene Transfer is Achieved by Infection with the Dual AAV2/5-ABCA4 Vectors In Vitro:

(31) By PCR analysis of DNA extracted from COS-7 cells (FIG. 3), junctions between the 5′ and 3′ ABCA4 sequences were detected following co-infection with AAV2/5-CMV-5′ABCA4-mAP and AAV2/5-mAP-3′ABCA4 vectors (lanes 9 and 10), or co-transfected with the linearized vector plasmids (lane 6), indicating AP-mediated intermolecular recombination between the vectors and intracellular reconstitution of the full ABCA4 expression cassette, as shown by the presence of a 1.3 kb PCR product. This result was confirmed in other cell lines, e.g. in HEK293. By RT-PCR analysis of RNA extracted from HEK293 cells (FIG. 4), a specific band of 0.3 kb corresponding to spliced ABCA4 mRNA was clearly detected in cells transfected with the control plasmid (lane 5), co-transfected with the linearized 5′ and 3′ AAV vector plasmids (lane 4), or co-infected with the 5′ and 3′ AAV2/5 vectors (lane 6). A faint band of the same size was also detected in untreated cells (lane 1) and in cells transfected with a single AAV vector plasmid (lanes 2 and 3), but the signal intensity was much lower. It is possible that the HEK293 cells express low level of ABCA4 mRNA or an mRNA with sequence homology (e.g. encoding another ABC transporter). However, the experiment indicated that AP-mediated intermolecular recombination between the dual vectors actually achieved reconstitution of a full-length, transcriptionally active ABCA4 expression cassette. This result was confirmed in other cell lines, e.g. in HeLa.

(32) By immuno-fluorescence microscopy analysis of HeLa cells (FIG. 5), the PCR and RT-PCR results were confirmed since a specific signal was detected by the anti-ABCA4 3F4 antibody in cells co-infected with the dual AAV2/5-ABCA4 vectors, indicating expression of the ABCA4 protein following intermolecular recombination between the 5′ and 3′ vector genomes. This result was confirmed in HEK293 cells.

(33) ABCA4 Gene Transfer is Achieved In Vivo by Intramuscular Injection of the Dual AAV2/5-ABCA4 Vectors in the Mouse Skeletal Muscle.

(34) Injection of a mix of AAV2/5-CMV-5′ABCA4-mAP and AAV2/5-mAP-3′ABCA4 vectors was performed into the tibialis anterior muscles of C57/BL6 mice to test ABCA4 gene transfer in vivo in terminally differentiated cells that do not express ABCA4.

(35) PCR analysis of DNA extracted from muscle samples indicated that both the 5′ABCA4 and 3′ABCA4 vector genomes were present within the injected muscle cells, and that junction between both vectors through AP-mediated recombination actually occurred in all four injected muscles (FIG. 6).
RT-PCR analysis of RNA extracted from muscle samples indicated that transcription and splicing of the reconstituted ABCA4 expression cassette also occurred in the injected muscles, as shown by detection of two overlapping fragments spanning the full-length transcript (3.3 kb from the start codon to downstream of the splice acceptor, and 3.8 kb from upstream of the splice donor to the stop codon). Indeed, the 3.3 kb fragment corresponding to the 5′ half of ABCA4 mRNA was detected in 3 of the injected muscles, and the 3.8 kb fragment corresponding to the 3′ half of ABCA4 mRNA was detected in all 4 injected muscles (FIG. 7).
Immuno-fluorescence microscopy analysis of muscles sections using the 3F4 monoclonal antibody was finally conducted on both non-injected mouse muscles and muscles injected with the dual AAV2/5 vectors (FIG. 8). A specific fluorescent signal was detected only in muscles injected with the AAV vectors. Although the signal was weak and detected only in a few muscle fibers (which could be expected since transduction with AAV5 vectors is poorly efficient in skeletal muscles), this result confirmed that the ABCA4 protein was actually expressed by the dual AAV vectors in vivo.

(36) ABCA4 Gene Transfer is Achieved In Vivo by Subretinal Injection of the Dual AAV2/5-ABCA4 Vectors in the Mouse Eye:

(37) Administration of 2.8×10.sup.9 vg of AAV2/5-CMV-5′ABCA4-mAP and 2.4×10.sup.9 vg of AAV2/5-mAP-3′ABCA4 vectors was performed by subretinal injection into the eye of Abca4.sup.−/− mice.

(38) Quantitative PCR analysis of reverse transcribed neuroretinal RNA using a F primer situated in exon 21 of the 5′ vector and a R primer situated in exon 22 of the 3′ vector demonstrated the amplification of a junction fragment specifically in the injected eyes (FIG. 9). No amplification was detected in the eyes from control Abca4+/−(primers specific for the human gene) or Abca4−/− mice. These results indicate that the 5′ABCA4 and 3′ABCA4 vector genomes were present within the injected retina cells, and that junction between both vectors through AP-mediated recombination occurred in all injected eyes. Expression was variable likely due to the difference in the efficiency of detachment per eye. RT-PCR analysis confirmed these results with a fragment of the correct size (183 bp) being detected only in the injected eyes. No amplification was detected in the absence of reverse transcription, excluding the possibility of amplification from a DNA template.
To further confirm that recombination did occur, the qPCR fragments were directly sequenced. Sequence alignment with the ABCA4 coding sequence showed that the amplified product corresponded to the fusion of exon 21-exon 22 following intermolecular recombination and splicing of the intervening alkaline phosphatase-containing intron sequence.

(39) ABCA4 Transgene Expression Following Subretinal Injection of the Dual AAV2/5-ABCA4 Vectors Appears Higher with the RK Promoter Compared to the CMV Promoter, in Both the Mouse and the Rat Eye:

(40) Quantitative PCR analysis of reverse transcribed neuroretinal RNA was performed as described above after subretinal administration of 1.4×10.sup.9 vg of AAV2/5-CMV-5′ABCA4-mAP or 1.5 to 5×10.sup.9 vg of AAV2/5-RK-5′ABCA4-mAP vector, together with 1.2×10.sup.9 vg or 5×10.sup.9 vg of AAV2/5-mAP-3′ABCA4 into the eye of Abca4.sup.−/− mice (FIG. 10). The 183 bp amplification product corresponding to human ABCA4 exon 21-exon 22 junction was detected only in Abca4.sup.−/− mice injected with the dual vectors and not in non-injected wild-type (Abca4.sup.−/−) and Abca4.sup.−/− mice. Expression levels of human ABCA4 mRNA in the injected neuroretina were approximately 1.6-fold higher when expressed from the photoreceptor-specific RK promoter as compare to the ubiquitous CMV promoter regardless of dose.

(41) The same quantitative PCR analysis of reverse transcribed neuroretinal RNA was performed after subretinal administration of vectors in Sprague Dawley rats (FIG. 11). Rats were injected with 3.7×10.sup.9 vg of AAV2/5-RK-5′ABCA4-mAP vector alone, 3.7×10.sup.9 vg of AAV2/5-mAP-3′ABCA4 vector alone, a mix of 1.85×10.sup.9 vg of AAV2/5-RK-5′ABCA4-mAP and 1.85×10.sup.9 vg of AAV2/5-mAP-3′ABCA4 vectors, or a mix of 1.85×10.sup.9 vg of AAV2/5-CMV-5′ABCA4-mAP and 1.85×10.sup.9 vg of AAV2/5-mAP-3′ABCA4 vectors. The 183 bp amplification product corresponding to human ABCA4 exon 21-exon 22 junction was detected only in rats injected with the dual vectors, and not in rats injected with either the RK-5′ABCA4-AP or the mAP-3′ABCA4 alone or in non-injected rats. Similarly to the result obtained in the mice, human ABCA4 mRNA expression levels in the rat retinas injected with the dual vectors were found higher (approximately 9.5-fold) when expressed from the photoreceptor-specific RK promoter as compare to the ubiquitous CMV promoter.

REFERENCES

(42) Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure. Ayuso E, Mingozzi F, Montane J, Leon X, Anguela X M, Haurigot V, Edmonson S A, Africa L, Zhou S, High K A, Bosch F, Wright J F. High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther. 2010 April; 17(4):503-10. Ghosh A, Yue Y, Lai Y, Duan D. A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol Ther. 2008 January; 16(1):124-30. Grimm D, Kay M A, Kleinschmidt J A. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther. 2003 June; 7(6):839-50. Khani S C, Pawlyk B S, Bulgakov O V, Kasperek E, Young J E, Adamian M, Sun X, Smith A J, Ali R R, Li T. AAV-mediated expression targeting of rod and cone photoreceptors with a human rhodopsin kinase promoter. Invest Ophthalmol Vis Sci. 2007 September; 48(9):3954-61. Salvetti A, Oreve S, Chadeuf G, Favre D, Cherel Y, Champion-Arnaud P, David-Ameline J, Moullier P. Factors influencing recombinant adeno-associated virus production. Hum Gene Ther. 1998 Mar. 20; 9(5):695-706. Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther. 2010 January; 18(1):80-6.